AI-driven volumetric approach for automatic chemotherapy response assessment in colorectal liver metastases
Marwan Abbas1,2, Gustavo Andrade-Miranda3, Vincent Bourbonne1,2,4
1LaTIM UMR 1101, Inserm, Brest, France.
Objectives:
This study evaluates the clinical utility of an artificial intelligence (AI)-driven volumetric approach for assessing treatment response in colorectal liver metastases (CRLM) compared to conventional RECIST 1.1 measurements.
Methods:
We developed and validated an AI segmentation pipeline using the nnU-Net framework trained on 476 CT scans from three datasets (LiTS, MetaRec, and MetaBrest). Performance was evaluated on 112 held-out CT scans from MetaBrest. For clinical validation, 157 patients with CRLM from the PRODIGE 9-FFCD clinical trial with baseline and 3-month follow-up CT scans were assessed using both RECIST 1.1 and AI-volumetric methods. Overall survival analysis was performed to compare the prognostic value of both approaches.
Results:
The nnU-Net model achieved a Dice similarity coefficient of 0.775 ± 0.211, with performance varying by lesion size (large: 0.899 ± 0.046; medium: 0.821 ± 0.135; small: 0.566 ± 0.330). In the overall validation cohort, both RECIST 1.1 and volumetric assessment demonstrated significant prognostic value for overall survival (p < 0.0001). In patients with liver-only metastases (n = 43), volumetric assessment showed significant prognostic stratification (p = 0.0150 at -30% threshold; p = 0.0409 at -50% threshold), while RECIST 1.1 failed to achieve statistical significance (p = 0.2088).
Conclusions:
AI-driven volumetric assessment of CRLM provides significant prognostic information that complements or potentially surpasses conventional RECIST 1.1 measurements, particularly in patients with liver-limited metastatic disease. Automation through deep learning makes comprehensive 3D evaluation feasible in clinical routine.
Key Points:
Question Can AI-powered volumetric assessment of colorectal liver metastases improve prognostic stratification for overall survival compared with conventional RECIST 1.1 criteria? Findings AI-based volumetric tumor burden showed strong prognostic value for overall survival and provided superior risk stratification compared with RECIST 1.1 in liver-only metastatic disease. Clinical relevance Automated deep learning-based volumetric assessment enables comprehensive 3D evaluation of colorectal liver metastases, overcoming historical barriers and potentially improving prognostic assessment and clinical decision-making.
